Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) hit a new 52-week high Friday as it is currently trading at $49.53, above its previous 52-week high of $49.48 with 795,239 shares traded as of 2:45 p.m. ET. Average volume has been 754,200 shares over the past 30 days.
Cubist has a market cap of $3.1 billion and is part of the
industry. Shares are up 24.7% year to date as of the close of trading on Thursday.
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company has a P/E ratio of 31.8, below the average drugs industry P/E ratio of 33.1 and above the S&P 500 P/E ratio of 17.7.
- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
TheStreet Ratings rates Cubist as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full
52-week high stocks
or get investment ideas from our
FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!
Free download now